Presented by presented by
Star Trek meets medical devices with tricorder contest by Qualcomm
Jeffrey Clark - Posted: 9/15/2014
Welcome to the intersection of science fiction and the medical device industry. Qualcomm is sponsoring the Tricorder X contest to create an affordable, handheld device that consumers can use to diagnose their medical conditions at home. The contest’s[...]
Google, Apple, others frustrated by regulatory hurdles for new tech
Jeffrey Clark - Posted: 9/12/2014
This is a fantastic article from the Associated Press on the growing pains felt by Silicon Valley entrepreneurs venturing into the healthcare industry.  Unlike technology where companies can launch a product unabated, companies like Google, Apple and[...]
Third weight loss treatment in past two years approved by FDA
Jeffrey Clark - Posted: 9/11/2014
For the third time in about two years, the Food and Drug Administration has approved a new weight-loss pill.  On Wednesday, FDA released approval to Orexigen Therapeutics oral drug Contrave, for use in chronic weight management along with a low-calor[...]
The next big class of blockbuster drugs?
Jeffrey Clark - Posted: 9/10/2014
Statins are so yesterday. Instead, drug companies are chasing a new class of drugs which aim to lower levels of LDL, or bad cholesterol. This could be a $10 billion market according to Leonard Schleifer, CEO of Regeneron.
To Infinity and beyond: Meet AbbVies newest partner
Jeffrey Clark - Posted: 9/9/2014
Under an agreement announced last week, AbbVie will partner with Infinity Pharma to develop blood cancer treatments. The Cambridge-based company will receive an upfront payment of $275 million and is eligible to receive up to $530 million in addition[...]
Pfizer, Astrazeneca back on?
Jeffrey Clark - Posted: 9/8/2014
There are rumors that Pfizer will again approach AstraZeneca about a takeover. Remember that under UK law, any discussions between Pfizer-AstraZeneca were forced into a cooling off period that began earlier this summer after protracted negotiations f[...]
GSK, others lead the way with expedited Ebola vaccine testing
Jeffrey Clark - Posted: 9/3/2014
GSK has been provided rapid approval by the FDA to start an experimental vaccine against Ebola in humans next week. This is part of a race by the World Health Organization and the National Institutes of Health to deliver a treatment to a rapidly spre[...]
Roche and Intermune CEOs share the spotlight
Jeffrey Clark - Posted: 8/29/2014
Roche CEO Severin Schwan is joined by Intermune CEO Dan Welch to discuss Roches $8.3B acquisition of Intermune in what is the largest deal for Roche since Genentech. Pirfenidone is an orally active, small molecule drug for fibrosis. Pirfenidone is ap[...]
IRS struggling with medical-device tax under Affordable Care Act
Jeffrey Clark - Posted: 8/27/2014
The medical device tax is falling short. The revenue tax on medical device sales that was passed to help fund the Affordable Care Act is only raising 75% of expected revenue.  Apparently, the shortfall is largely due to challenges at the IRS in colle[...]
Former senators tapped to lobby for Medtronic-Covidien merger
Jeffrey Clark - Posted: 8/26/2014
Medtronic has enlisted former Senators John Breaux from Louisiana and Trent Lott from Virginia to lobby for the companys pending merger with Covidien.  Public records show that Medtronic has paid the Breaux-Lott Leadership Group $200,000 to discuss b[...]
Zafgen takes different approach toward treating obesity
Jeffrey Clark - Posted: 8/22/2014
Zafgen CEO Tom Hughes discusses the companys focus on obesity with CNBC. Hughes says the new drug works to impact the way the body handles fat. Just more than two years ago, Arena Pharmaceuticals and Vivus won approval for the first new obesity drugs[...]
Forbes: Preventing A Dangerous Race To The Bottom In Biotechnology
Jeffrey Clark - Posted: 8/21/2014
In an op-ed published through, University of Chicago economist Tomas Philipson debates the effect of biosimilars in terms of naming, quality and price differentiation as they begin to enter the healthcare market.  Philipson, from the Harri[...]
Allergan approaches Salix in attempt to thwart Valeant deal
Jeffrey Clark - Posted: 8/20/2014
Allergan has approached Raleigh-based Salix Pharmaceuticals about a potential acquisition that could thwart Valeant’s hostile bid for the company. While it is unclear where the talks stand, Allergan could strike a takeover deal with Salix or another [...]
Roche acquisition rumor disavowed by Chugai
Jeffrey Clark - Posted: 8/19/2014
Yesterday, the industry was abuzz with the idea Roche was planning to buyout the 40% of Chugai Pharmaceuticals that it does not already own for almost $10B. Bloomberg, Reuters and the Wall Street Journal all reported as such. Today, a much different [...]
Regeneron CEO: How I became a billionaire
Jeffrey Clark - Posted: 8/18/2014
Regeneron CEO Leonard Schleifer shares his story with CNN, from founding the company and the journey to success to now become a billionaire.
Cool technology: Sharks hold the key to curing cancer?
Jeffrey Clark - Posted: 8/15/2014
Cool technology: Sharks hold the key to curing cancer?
Allergan v. Valeant: Update and Insight
Jeffrey Clark - Posted: 8/13/2014
The New York Times offers a much-needed update and insight into the strategy behind Allergan vs. Valeant. NY Times
Will life sciences step up to combat Ebola?
Jeffrey Clark - Posted: 8/12/2014
Every 1-2 years the life sciences industry is faced with a world health crisis.  We've seen the script play out with HIV, SARS, bird flu, mad cow disease and now Ebola. In this CNBC interview, Mount Sinai CEO Ken Davis explains how the hospital [...]
MannKind licenses inhaled insulin to Sanofi in up to $925M deal
Jeffrey Clark - Posted: 8/11/2014
MannKind has licensed its newly approved inhaled insulin product, Afrezza, to Sanofi.  Less than two months after its FDA approval, Afrezza now belongs to Sanofi for global development and commercialization with hopes it will enter the market before [...]
GSK employees convicted, jailed in China scandal
Jeffrey Clark - Posted: 8/8/2014
Two American and British GSK employees are now in jail as a result of the company’s improprieties in China. Chinese officials would not allow family or foreign diplomats to attend the trial. The husband-and-wife business partners, Peter Humphrey, a B[...]
Lilly CEO on CNBC talks acquisitions, animal healthcare
Jeffrey Clark - Posted: 8/7/2014
The big large-scale combinations are not right for Lilly right now, says John Lechleiter, Eli Lilly CEO, discussing how the company plans to expand its pharmaceutical footprint through acquiring smaller companies. Also in this interview with CNBC, Le[...]
Ranking the top 25 biotechnology companies
Jeffrey Clark - Posted: 8/6/2014
Genetic Engineering and Biotechnology News has released its list of biggest biotechnology companies, ranked by market capitalization. For sure, the industry is doing well on Wall Street with a surge in overall valuations and more than 50 new companie[...]
Experimental treatment saves US Ebola patients
Jeffrey Clark - Posted: 8/4/2014
The story reads like something out of a science fiction movie. Three top secret, experimental vials stored at subzero temperatures are flown from a US lab to western Africa in a last-ditch effort to save two American missionary workers who had contra[...]
Catalent CEO touts successful IPO
Jeffrey Clark - Posted: 8/1/2014
Catalent CEO John Chiminski discusses the companys IPO and business strategy. Catalent is a lesser known brand in the life sciences industry buy happens to be the world leader in advanced drug technologies. Catalent works with pharmaceutical companie[...]
First shots fired between Novartis, Amgen in biosimilars battle
Jeffrey Clark - Posted: 7/30/2014
The FDA has agreed to review Sandozs biologics license application for Zarzio, its biosimilar version of Amgens Neupogen.  Neupogen is one of the products that set the foundation and helped build Amgen into what it is today.  The treatment is indicat[...]
The next big class of blo[...]
Statins are so yesterday. Instead, drug companies are chasing a new class of drugs which aim to l[...]
To Infinity and beyond: M[...]
Under an agreement announced last week, AbbVie will partner with Infinity Pharma to develop blood ca[...]
Roche and Intermune CEOs [...]
Roche CEO Severin Schwan is joined by Intermune CEO Dan Welch to discuss Roche’s $8.3B acquisition o[...]
Zafgen takes different ap[...]
Zafgen CEO Tom Hughes discusses the company’s focus on obesity with CNBC. Hughes says the new drug w[...]
Regeneron CEO: How I beca[...]
Regeneron CEO Leonard Schleifer shares his story with CNN, from founding the company and the journey[...]